Idexx Laboratories (IDXX) Stock
Leading provider of veterinary and water diagnostic tests. Here's the price, business snapshot, and what's worth knowing about Idexx Laboratories in October 2026.
IDEXX Laboratories is a leading provider of diagnostic tests, instruments and software for the animal health and water testing markets. The company sells a mix of instruments and high-margin consumables as well as practice-management and diagnostic software that together create recurring revenue streams and close customer relationships with veterinary clinics and laboratories. IDEXX benefits from structural trends such as rising pet ownership and increased spending on companion animal care, while also operating in water and livestock testing markets. Investors should note it is exposed to competitive pressures, regulatory requirements and technological change, and its performance can vary with regional veterinary spending and currency moves. The company’s market cap (around $51 billion) reflects sizeable scale and long-term growth expectations, but this is general information only and not personal financial advice — suitability depends on your goals, risk tolerance and timeframe.
Why It’s Moving
IDEXX Acquires CoVetAI and Sets Q3 Earnings Date, Fueling Analyst Optimism
- IDEXX completed the acquisition of CoVetAI Inc., marking a significant expansion into AI-enhanced animal health diagnostics.
- The company confirmed it will report 2026 third quarter financial results on Monday, November 2, 2026, before market open.
- Chicago Pacific Founders exited its investment in CoVetAI following the IDEXX deal, highlighting strong investor interest in specialist animal health technology.
IDEXX Acquires CoVetAI and Sets Q3 Earnings Date, Fueling Analyst Optimism
- IDEXX completed the acquisition of CoVetAI Inc., marking a significant expansion into AI-enhanced animal health diagnostics.
- The company confirmed it will report 2026 third quarter financial results on Monday, November 2, 2026, before market open.
- Chicago Pacific Founders exited its investment in CoVetAI following the IDEXX deal, highlighting strong investor interest in specialist animal health technology.
